Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)

Corral, Julieta; Espinàs, Josep Alfons; Cots, Francesc; Pareja, Laura; Solá, J.; Font, Rebeca; Borrás, Josep María

doi:10.1186/s12913-015-0725-3

Cited by 44 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Spanish study -which recruited patients from 9 hospitals with a minimum of 50 treated lung cancer cases per year -reported lung cancer-related hospital spending of ca. D 14,800 in a three-year timeframe [9] compared to inpatient hospital expenditures of D 13,300 in our sample. A secondary databased cross-country comparison of NSCLC patients yielded lung cancer-related spending of ca.…”

Section: Discussionmentioning

confidence: 96%

“…Clinically, these parameters are of utmost importance as they impact survival prognosis and the decision for a distinct treatment regimen [20]. Evidence on their cost impact, however, is contradictory [9,17,18]. We best possibly accounted for the effect of different disease stages by including baseline metastases and multiple tumors in our regressions.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, there is growing international interest in quantifying the economic dimension of lung cancer care [6][7][8][9], but regarding Germany data on budget impact [10,11] or expenditures per case [12] are widely lacking.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens

et al. 2015

View full text Add to dashboard Cite

“…In the Netherlands, official data on costs for lung cancer, CHD, stroke and COPD were available 23. Costs of smoking‐related diseases were obtained from the literature in Germany 24, 25, 26, 27 and Spain 28, 29, 30, 31, 32. Further details are found in country‐specific technical annexes 16, 17, 18, 19, 20.…”

Section: Methodsmentioning

confidence: 99%

Estimates of costs for modelling return on investment from smoking cessation interventions

Trapero-Bertran

Leidl²,

Muñoz

et al. 2018

Addiction

View full text Add to dashboard Cite

Background and aimsModelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe‐wide ROI model [European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD)].DesignFocused search of administrative and published data. A standardized checklist was developed in order to ensure consistency in methods of data collection.Setting and participantsAdult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For passive smoking‐related costs, child population (0–15 years) was also included.MeasurementsCosts of treating smoking‐attributable diseases; productivity losses due to smoking‐attributable absenteeism; and costs of implementing smoking cessation interventions.FindingsAnnual costs (per case) of treating smoking attributable lung cancer were between €5074 (Hungary) and €52 106 (Germany); coronary heart disease between €1521 (Spain) and €3955 (Netherlands); chronic obstructive pulmonary disease between €1280 (England) and €4199 (Spain); stroke between €1829 (Hungary) and €14 880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to be: for standard duration of varenicline between €225 (England) and €465 (Hungary); for bupropion between €25 (Hungary) and €220 (Germany). Costs (per recipient) of providing behavioural support were also wide‐ranging: one‐to‐one behavioural support between €34 (Hungary) and €474 (Netherlands); and group‐based behavioural support between €12 (Hungary) and €257 (Germany). The costs (per recipient) of delivering brief physician advice were: €24 (England); €9 (Germany); €4 (Hungary); €33 (Netherlands); and €27 (Spain).ConclusionsCosts of treating smoking‐attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.

show abstract

“…For each country, the annual health‐care costs for an individual with each of the diseases were estimated based on a systematic literature review 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55. Costs relate to prevalent cases of disease.…”

Section: Methodsmentioning

confidence: 99%

Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation

Coyle

Lester‐George

et al. 2017

Addiction

View full text Add to dashboard Cite

Background and AimsAlthough clear benefits are associated with reducing smoking, there is increasing pressure on public health providers to justify investment in tobacco control measures. Decision‐makers need tools to assess the Return on Investment (ROI)/cost‐effectiveness of programmes. The EQUIPT project adapted an ROI tool for England to four European countries (Germany, the Netherlands, Spain and Hungary). EQUIPTMOD, the economic model at the core of the ROI tool, is designed to assess the efficiency of packages of smoking cessation interventions. The objective of this paper is to describe the methods for EQUIPTMOD and identify key outcomes associated with continued and cessation of smoking.MethodsEQUIPTMOD uses a Markov model to estimate life‐time costs, quality‐adjusted life years (QALYs) and life years associated with a current and former smoker. It uses population data on smoking prevalence, disease prevalence, mortality and the impact of smoking combined with associated costs and utility effects of disease. To illustrate the tool's potential, costs, QALYs and life expectancy were estimated for the average current smoker for five countries based on the assumptions that they continue and that they cease smoking over the next 12 months. Costs and effects were discounted at country‐specific rates.ResultsFor illustration, over a life‐time horizon, not quitting smoking within the next 12 months in England will reduce life expectancy by 0.66, reduce QALYs by 1.09 and result in £4961 higher disease‐related health care costs than if the smoker ceased smoking in the next 12 months. For all age–sex categories, costs were lower and QALYs higher for those who quit smoking in the 12 months than those who continued.ConclusionsEQUIPTMOD facilitates assessment of the cost effectiveness of smoking cessation strategies. The demonstrated results indicate large potential benefits from smoking cessation at both an individual and population level.

show abstract

Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)

Cited by 44 publications

References 16 publications

Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens

Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens

Estimates of costs for modelling return on investment from smoking cessation interventions

Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation

Contact Info

Product

Resources

About